Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era.

The CPI2 prognostic model, using 14 clinical parameters, outperforms the IMDC model with 0.72 discriminative accuracy in metastatic clear cell renal cell carcinoma.

• Why it matters: Accurate prognostic models are essential for guiding treatment and clinical trial design in metastatic ccRCC, especially in the era of immune checkpoint inhibitors, but existing models need validation and improvement.
• What they did: Researchers developed the CPI2 model from clinical trial data of 1,096 and 651 patients, selecting predictors through Cox regression and bootstrapping, then validated it externally against the IMDC model.
• The result: CPI2 demonstrated superior discriminative accuracy (0.72 vs. 0.61) and adequate calibration, enabling better risk stratification and potential for more personalized treatment approaches in metastatic ccRCC.